학술논문

A phase 3, randomized, open-label study of nivolumab combined with cabozantinib vs sunitinib in patients with previously untreated advanced or metastatic renal cell carcinoma (RCC; CheckMate 9ER).
Document Type
Journal
Source
JOURNAL OF CLINICAL ONCOLOGY; MAY 20 2018, 36 15, 1p. Supplement: S
Subject
Language
English
ISSN
15277755